Navigation Links
New way to control protein activity could lead to cancer therapies
Date:9/28/2008

STANFORD, Calif. Investigators at the Stanford University School of Medicine have found a way to quickly and reversibly fine-tune the activity of individual proteins in cells and living mammals, providing a powerful new laboratory tool for identifying more precisely than ever before the functions of different proteins.

The new technique also could help to speed the development of therapies in which cancer-fighting proteins are selectively delivered to tumors.

The procedure, described in a Nature Medicine paper to be published online Sept. 28, appears to be broadly applicable to efforts to understand the biological roles of all kinds of proteins, including those that are secreted by cells. This category includes many potent intercellular signaling proteins that can influence the immune system, for example by attracting its attention to an existing tumor.

"We have yet to find a protein the system doesn't work with," said senior author Steve Thorne, PhD, an assistant professor at the University of Pittsburgh who was involved in the work while a research associate at Stanford. The work was conducted under the direction of Chris Contag, PhD, associate professor of pediatrics, of radiology and of microbiology and immunology; and Tom Wandless, PhD, assistant professor of chemical and systems biology.

This technique, which was tested in mice, involves pairing specially bioengineered proteins with a drug, aptly named Shield-1, that prevents the proteins from being degraded.

This approach stands in contrast to current ways of learning about proteins' functions, which are largely based on impeding a cell's production of the protein. Unfortunately, that cellular process can be slow and cumbersome, meaning that scientists get a sluggish response to such manipulations. In addition, current methods to perturb protein function are either irreversible once a protein's product
'/>"/>

Contact: Bruce Goldman
goldmanb@stanford.edu
650-725-2106
Stanford University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Chromatin remodeling complex connected to DNA damage control
2. More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag
3. New Asthma Guidelines Stress Disease Control
4. UI nursing researcher to study post-operative pain control
5. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio
6. Hispanics hypertension better controlled with equal access to care
7. Detroit Metro Tower Air Traffic Controllers File Lawsuit Alleging Improper Mold Removal and Health Effects
8. Maternal depression and controlling behavior associated with increased stress response in infants
9. New Website Helps Women Be Fit, Sexy and in Control!
10. Controlling for size may also prevent cancer
11. Cancer control in Europe works; now it is time to extend it to poorer countries

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...TOWN, Ariz., Dec. 3 The ...ay that it has acquired SunView Care Center, an op...Youngtown, Arizona, a sister community adjacent to...isition was effective December 1, 2009. ,, (Log...LATH168LOGO ) ,, "We are pleased to be adding ...
(Date:12/3/2009)...RBOR, Mich., Dec. 3 A majority of ...reform legislation, but most lack confidence that ...al care will improve in the next year, according t..., Sixty percent of survey respondents said they be...healthcare reform legislation. Only about one in f...
(Date:12/2/2009)...RAPIDS, Mich., Dec. 3 Van Andel Re...d precisely how the plant hormone abscisic acid (A...spond to environmental stresses such as drought an... Nature , could help engineer crops that thrive in...obal food shortages. The findings could also have...
(Date:12/2/2009)...EW YORK, Dec. 2 Reportlinker.com a...lable in its catalogue: ,, Sterilization Tech...rtlinker.com/p0166820/Sterilization-Technologies-T...n sales of capital equipment to the sterilization ...und annual growth rate for 2009-2014. ,, Explai...
(Date:12/2/2009)...NEW YORK, Dec. 2 Reportlinker.com ...ilable in its catalogue: ,, Kinase Inhibitors....com/p0166819/Kinase-Inhibitors-Global-Markets.htm...ing data for the years 2005 through 2008, and proj...rates (CAGRs) through 2014 ,, An overview of t...
Breaking Medicine News(10 mins):Health News:The Ensign Group Acquires Arizona Skilled Nursing Facility 2Health News:Thomson Reuters Survey: Most Americans Support Public Option in Healthcare Reform Legislation but Are Skeptical Healthcare Will Improve in 2010 2Health News:VAI Researchers Find Long Awaited Key to Creating Drought Resistant Crops 2Health News:VAI Researchers Find Long Awaited Key to Creating Drought Resistant Crops 3Health News:VAI Researchers Find Long Awaited Key to Creating Drought Resistant Crops 4Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 2Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 3Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 4Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 5Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 6Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 7Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 8Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 9Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 10Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 11Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 12Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 13Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 2Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 3Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 4Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 5Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 6Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 7Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 8Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 9Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 10Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 11Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 12Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 13Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 14Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 15
...on suggests that daily use of inhaled steroids may... Dr. Gregory Sawicki insists that a stud... shown that over a period of one-year, children wh... The findings remained same even when the sever...
...eth's oral contraceptive Lybrel, which is designed...ngeles Times reports. Lybrel, which contains a lo...n traditional oral contraceptives, is taken 365 da... According to Wyeth, 59% of women taking Lybr...
...joined forces with Canadian biotech company GangaG... fight against food poisoning . They are e...hods for the control of Campylobacter the commone...ry and other animals and cause millions of cases o...
...ditions for nurses are safer for elderly intensive...eport , led by researchers that measured rates of...ed infections are the number six cause of death in...ety of ICUs if systematic improvements to their wo...
...ck have found that sexual orientation has a real e...ating with a map in a car but that old age does n...nd withers all mens minds alike just ahead of wome... women). As expected they found men outperformed w...
...nts with asthma are more likely to have severe ast.... The study was conducted by a team of res...and colleagues at Emory University. As par... one of the largest diverse surveys of all asthma ...
Other Medicine News:Health News:Use of Inhaled Steroids on Daily Basis may Not Control Childhood Asthma 2Health News:FDA Approves Wyeth's Oral Contraceptive Lybrel 2Health News:Experts to Develop New Weapons Against Food Poisoning 2Health News:Experts to Develop New Weapons Against Food Poisoning 3Health News:Better Working Conditions for Nurses Might Decrease Patient Infections 2Health News:Better Working Conditions for Nurses Might Decrease Patient Infections 3Health News:Obesity Might Lead to Severe Persistent Asthma Attacks: Study 2
(Date:12/2/2009)...ewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEP... U.S. District Court in Delaware against Teva Phar...ent Nos. 7,132,570 (the ",570 Patent"), 7,297,346 ...") for the Cephalon product NUVIGIL® (armodaf...eriod of marketing exclusivity for NUVIGIL that ex...
(Date:12/2/2009)...wswire/ -- Reportlinker.com announces that a new m...e: ,, Pharmaceutical Contract Manufacturing -...inker.com/p0164248/Pharmaceutical-Contract-Manufac... pharma industry faces numerous challenges in the ... rising cost of new product development, declining...
(Date:12/2/2009)...ewswire-USNewswire/ -- Jupiter Medical Center ha... tools available into its imaging program, the new... system delivers highly detailed images of the hum...d unique applications, including dual breast scann... with renal dysfunction. This results in shorter ...
Breaking Medicine Technology:Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5Jupiter Medical Center Announces New High-Definition MRI System 2Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 1Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 2Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 3Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 4Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 5Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 6Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 7Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 8Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 9Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 10Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 11Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 12Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 13Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 14Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results 57573 15State of Oklahoma Offers Invisible Bracelet Health Benefit 57571 1State of Oklahoma Offers Invisible Bracelet Health Benefit 57571 2Immucor to Announce Fiscal First Quarter Financial Results on Thursday October 1 2009 57569 1
...w comparable safety for complex patients treated w...y , , NATICK, Mass., Feb. 18 Boston Scientific C...cation of results from its landmark SYNTAX(TM) tri... of Medicine. In the study, percutaneous coronary...) Paclitaxel-Eluting Coronary Stent System was com...
...TLE, Feb. 18 Cell Therapeutics, Inc.,(Nasdaq and ... efficacy data,from the phase III trial of pixantr... benefit for pixantrone when used as single agent ...essive non-Hodgkin,s lymphoma (NHL). On an,intent-...ved a complete,remission did so during the first 2...
Other Medicine Technology:New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX(TM) Trial 2New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX(TM) Trial 3New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX(TM) Trial 4New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX(TM) Trial 5Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma 2Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma 3Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma 4
Magic WALLSTENT® Stent System
...edical's universal programmer platform, the Model ...th St. Jude Medical® bradycardia and tachycard...tions. Features a large, color display on a touch...fers continuous, simultaneous display of surface E...
Finnpipette 384
Liberte™ Coronary Stent System
Medicine Products: